[Federal Register Volume 64, Number 137 (Monday, July 19, 1999)]
[Notices]
[Page 38678]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-18375]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the US 
Government and is available for licensing in the US in accordance with 
35 U.S.C. 207 to achieve expeditious commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing.

ADDRESSES: Licensing information and a copy of the U.S. patent 
application listed below may be obtained by contacting Susan S. Rucker, 
J.D., at the Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804; telephone: 301/496-7056 ext. 245; fax: 301/402-0220; e-
mail:[email protected]. A signed Confidential Disclosure Agreement will be 
required to receive a copy of the patent application.

Immunoadhesins and Methods of Production Thereof

KG Csaky, E Anglade, DM Sullivan (all of NEI), WJ Larochelle (NCI)
Serial No. 08/814,567 filed 10 Mar 97

    This patent application relates to the field of immunoadhesins. 
Immunoadhesins, also known as immunoligands, Ig- or Fc- fusion proteins 
or chimeras are chimeric molecules comprised of a non-immunoglobulin 
binding region (e.g., cell surface receptor, ligand, cell adhesion 
molecule) and an antibody constant domain. Such molecules can be used 
to identify receptors or ligands, in structure-function studies or as 
therapeutic agents.
    In particular, the application describes a method for producing 
immunoadhesins which utilizes a replication-deficient adenoviral 
expression system. This system addresses some of the defects of other 
immunoadhesion production systems utilizing transfection of plasmid DNA 
in either a transient or stable system by providing efficient, high 
level gene expression, appropriate assembly/post-translation 
modification and ease of purification. Particular immunoadhesins which 
have been produced using this system are incorporate IL-10, IL-2, IL-
13, IL2ra, IL-1ra, mutant IL-4, ICAM, TGF-11, or TGF-
1223,225 as the non-immunoglobulin portion.
    This research has been published, in part, in Anglade, et al. 
``Interleukin-10 immunoadhesin production by a replication-defective 
adenovirus'' J. Immunol. Methods 202(1): 41-8 (March 10, 1997).

    Dated: July 13, 1999.
Jack Spiegel, Ph.D.,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 99-18375 Filed 7-16-99; 8:45 am]
BILLING CODE 4140-01-M